Keyphrases
Myasthenia Gravis
80%
Acetylcholine Receptor Antibody
67%
Eculizumab
63%
Nicotinic Acetylcholine Receptor (nAChR)
52%
Autoimmune Autonomic Ganglionopathy
51%
Autoantibodies
44%
Autonomic Dysfunction
43%
Ganglionic Acetylcholine Receptor
36%
Cerebrospinal Fluid
29%
Autonomic Symptoms
27%
Open-label Extension
27%
Clinical Features
26%
Anti-ganglionic Acetylcholine Receptor Antibodies
22%
Luciferase Immunoprecipitation Systems
21%
Japanese Patients
18%
Japan
18%
Placebo
17%
Autoimmune Disease
17%
Postural Orthostatic Tachycardia Syndrome
17%
Autoimmune Dysautonomia
16%
Autonomic Disorders
15%
Randomized Double-blind
15%
Placebo-controlled
15%
Transmembrane
13%
Muscle Weakness
13%
Intravenous Immunoglobulin (IVIg)
12%
Gastrointestinal Diseases
12%
Systemic Lupus Erythematosus
11%
Systemic Sclerosis
11%
Clinical Characteristics
11%
Autoimmune
11%
Pathogenicity
11%
Orthostatic Intolerance
11%
Acetylcholine Receptor (AChR)
10%
Head-up Tilt Test
10%
Luciferase
9%
Intravenous Immunoglobulin Therapy
9%
Sarcoidosis
9%
Multiple Sclerosis
9%
Autonomic Nervous System
9%
Achalasia
8%
Number of Patients
8%
Autoimmune Rheumatic Diseases
8%
Phase II Study
8%
Rituximab
8%
Myasthenia Gravis Activities of Daily Living
8%
Muscle Strength
8%
Dysautonomia
7%
Multifocal Motor Neuropathy
7%
Minimum number
7%
Immunology and Microbiology
Immunology
100%
Autoantibodies
71%
Nicotinic Acetylcholine Receptor
56%
Cholinergic Receptor Antibody
48%
Myasthenia gravis
40%
Eculizumab
23%
Immunoprecipitation
20%
Autoimmune Disease
19%
Immunity
19%
Immunotherapy
18%
Standing
15%
Intravenous Immunoglobulin
12%
Systemic Scleroderma
11%
Systemic Lupus Erythematosus
11%
Pathogenicity
11%
Autoimmune Rheumatic Disease
10%
Autonomic Nervous System
9%
Central Nervous System
9%
Multiple Sclerosis
8%
Rituximab
8%
Prevalence
8%
Autoimmune Encephalitis
7%
Transmembrane Activator and CAML Interactor
7%
B Cell Activating Factor
7%
Allele
7%
HLA DRB1 Antigen
7%
Myelin Oligodendrocyte Glycoprotein
7%
Clinical Immunology
7%
Thymus
7%
Primary Biliary Cirrhosis
7%
Immune System
7%
Optic Neuritis
7%
Adolescence
7%
Neurological System
7%
Blood Plasma
7%
Iodine-123
7%
Muscle Strength
6%
Potassium Channels
5%
Creatine Kinase Blood Level
5%
MHC Class II
5%
Medicine and Dentistry
Cholinergic Receptor Antibody
38%
Disease
29%
Autoimmune Autonomic Ganglionopathy
28%
Autonomic Dysfunction
22%
Cerebrospinal Fluid
22%
Placebo
17%
Clinical Feature
16%
Autoantibodies
15%
Myasthenia gravis
15%
Eculizumab
15%
Nicotinic Receptor
15%
Dysautonomia
14%
Cholinergic Receptor
10%
Postural Orthostatic Tachycardia Syndrome
9%
Sarcoidosis
9%
Immunoglobulin
9%
Orthostatic Intolerance
9%
Achalasia
8%
Diagnosis
8%
Systemic Lupus Erythematosus
7%
Intestinal Pseudoobstruction
7%
Diabetic Neuropathy
7%
Spinal Cord Disease
7%
Patient with Type 2 Diabetes
7%
Biological Marker
7%
Human T-Lymphotropic Virus 1
7%
Neurosarcoidosis
7%
Tropical Spastic Paraparesis
7%
Kleine-Levin Syndrome
7%
Herpes Simplex Encephalitis
7%
Tilt Table Test
7%
Multifocal Motor Neuropathy
7%
Cyclophosphamide
7%
Orexin
7%
Mogamulizumab
7%
Inclusion Body Myositis
7%
B-Cell Activating Factor
7%
Macroglossia
7%
Transmembrane Activator and CAML Interactor
7%
Disseminated Herpes Zoster
7%
Adolescence
7%
Aciclovir
7%
Pulse Rate
6%
Primary Central Nervous System Lymphoma
6%
Muscle Strength
5%
Immunotherapy
5%
Pleocytosis
5%
High Fever
5%
Cerebrospinal Fluid Analysis
5%